Canaccord Genuity Group Reaffirms “Buy” Rating for Intellia Therapeutics (NASDAQ:NTLA)
Canaccord Genuity Group reissued their buy rating on shares of Intellia Therapeutics (NASDAQ:NTLA – Free Report) in a report issued on Thursday morning, Benzinga reports. The brokerage currently has a $73.00 price target on the stock. A number of other equities analysts have also weighed in on NTLA. Wedbush reissued a neutral rating and issued […]
More Stories
Insider Selling: Twist Bioscience Co. (NASDAQ:TWST) Insider Sells 3,104 Shares of Stock
Twist Bioscience Co. (NASDAQ:TWST – Get Free Report) insider Dennis Cho sold 3,104 shares of Twist Bioscience stock in a...
DT Midstream, Inc. (NYSE:DTM) Given Average Rating of “Hold” by Brokerages
Shares of DT Midstream, Inc. (NYSE:DTM – Get Free Report) have been assigned an average recommendation of “Hold” from the...
Paradigm Oil and Gas (OTCMKTS:PDGO) & Coeur Mining (NYSE:CDE) Financial Contrast
Paradigm Oil and Gas (OTCMKTS:PDGO – Get Free Report) and Coeur Mining (NYSE:CDE – Get Free Report) are both oils/energy...
IBEX (NASDAQ:IBEX) versus Automatic Data Processing (NASDAQ:ADP) Financial Analysis
IBEX (NASDAQ:IBEX – Get Free Report) and Automatic Data Processing (NASDAQ:ADP – Get Free Report) are both business services companies,...
SiTime (NASDAQ:SITM) and TranSwitch (OTCMKTS:TXCCQ) Critical Review
SiTime (NASDAQ:SITM – Get Free Report) and TranSwitch (OTCMKTS:TXCCQ – Get Free Report) are both computer and technology companies, but...
Energy Fuels (UUUU) & The Competition Head-To-Head Review
Energy Fuels (NYSE:UUUU – Get Free Report) is one of 29 publicly-traded companies in the “Mining & quarrying of nonmetallic...